162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
Titel:
162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
Auteur:
Hamilton, E.P. Shapiro, C.L. Boni, V. Martin Jimenez, M. Del Conte, G. Cortés, J. Agrawal, L. Arkenau, H-T. Tan, A.R. Debruyne, P.R. Minchom, A.R. Rutten, A. Valdes-Albini, F. Yu, E. Suto, F. Cheng, F-C. Augustine, B. Cheng, B. Barrios, D. Hurvitz, S.A.